The IGL Group, based in France, has acquired Celsior® from Sanofi Genzyme for US$11.5 million.
Companies within the IGL Group develop research programmes that have led to the development of products designed specifically to improve organ recovery, preservation, transport and evaluation systems before transplant. The IGL-1® preservation solution is particularly well suited for expanded criteria donors.
Celsior®, producing liquid compositions for perfusion, reperfusion and preservations of organs, is part of the Sanofi Genzyme group, a global healthcare leader focused on the research, development, manufacturing and marketing of innovative therapeutic solutions.
Sanofi Genzyme is engaged in the research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi's core strength is in the healthcare sector, with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Oaklins' team in France advised the buyer in this transaction.
© Oaklins. All rights reserved. Oaklins refers to Oaklins International Inc. and/or one of its member firms, each of which is a separate legal entity. Please see www.oaklins.com/legal for further details.